Lilly to Acquire Ajax Therapeutics, Advancing Potential Breakthrough Therapy for MPNs

Eli Lilly and Company has announced the acquisition of Ajax Therapeutics, a biopharmaceutical company specializing in next-generation JAK inhibitors for myeloproliferative neoplasms (MPNs). Ajax's lead program, AJ1-11095, a first-in-class Type II JAK2 inhibitor, is currently in Phase 1 clinical development. The unique mode of binding JAK2 of AJ1-11095 could potentially offer more effective disease control compared to existing therapies for myelofibrosis and polycythemia vera.

Lilly has expressed its excitement about the potential of AJ1-11095 to provide deeper and more durable efficacy with a tolerability profile that could lead to longer therapy retention. The acquisition deal could see Ajax shareholders receiving up to $2.3 billion in cash, contingent on the achievement of specific clinical and regulatory milestones. The transaction is pending customary closing conditions and regulatory approvals. Ajax Therapeutics' pursuit of novel therapies for MPNs stems from a collaboration with Schrödinger, Inc., leveraging advanced computational structure-based drug discovery platforms.

The acquisition is poised to advance the development of AJ1-11095 and address the significant unmet needs of MPN patients. Both companies are optimistic about the potential of this acquisition to deliver an important new medicine to patients and hematologists in the near future.